Longeveron Inc. revenue
Longeveron Inc.'s revenue was $1.2m in fiscal 2025, down 49.9% on the year before. Since fiscal 2020 ($5.6m) it has grown at a compound -26.6% a year. Over the last twelve months it was $1.2m.
Revenue history
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 5,629 | 1,306 | 1,222 | 709 | 2,392 | 1,199 | 1,187 |
| Growth on the year before | — | −76.8% | −6.4% | −42.0% | +237.4% | −49.9% | — |
| Gross profit | 1,826 | 590 | 497 | 221 | 1,884 | 803 | 828 |
| Gross margin | 32.4% | 45.2% | 40.7% | 31.2% | 78.8% | 67.0% | 69.8% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Clinical Trial Revenue | $954,000 | 79.6% | ▼ 32.0% |
| Contract Manufacturing Revenue | $222,000 | 18.5% | ▼ 54.4% |
| Contract Manufacturing Lease Revenue | $23,000 | 1.9% | ▼ 95.4% |
From Longeveron Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Longeveron Inc. | $1.2m | -42.7% | 10.4% |
| Dare Bioscience, Inc. | $1.4m | 4366.5% | — |
| Shattuck Labs, Inc. | $1.0m | -66.6% | 5.2% |
| Cartesian Therapeutics, Inc. | $1.5m | 44.0% | -68.8% |
| Medicinova Inc | $920,481 | 875.7% | — |
| Absci Corp | $1.6m | -62.3% | -43.3% |
Compare with peers
- Dare Bioscience, Inc. revenue
- Shattuck Labs, Inc. revenue
- Cartesian Therapeutics, Inc. revenue
- Medicinova Inc revenue
- Absci Corp revenue
Head to head: DARE vs LGVNLGVN vs STTKLGVN vs RNACLGVN vs MNOV
More: Biotechnology stocks compared, Health Care sector, rankings of US companies